Theorem Clinical Research

Aeras

GHIT Fund awards $12M for neglected diseases, launches investment program

Thursday, March 20, 2014 02:22 PM

The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership bringing Japanese experience and investment to the global fight against infectious diseases, has announced three grants worth a total of $6.8 million to speed the development of innovative drugs for some of the world’s most neglected diseases—schistosomiasis, Chagas disease and parasitic roundworms.

More... »


NIBIO, Aeras, CREATE to advance Japanese TB vaccine technology

Wednesday, January 29, 2014 01:13 PM

Japan's National Institute of Biomedical Innovation (NIBIO), Aeras and Create Vaccine (CREATE) have signed a collaboration for the preclinical and clinical development of new mucosal tuberculosis (TB) vaccines based on NIBIO's human parainfluenza type-2 (rhPIV2) vector technology.

More... »


Aeras, GSK to jointly advance TB vaccine

Wednesday, October 10, 2012 11:56 AM

Aeras, a fully-integrated tuberculosis (TB) vaccine development organization, has signed an agreement with global healthcare company GlaxoSmithKline to jointly advance the clinical development of an investigational TB vaccine containing GSK's proprietary M72 antigen and AS01E adjuvant. 

More... »

Emergent receives NIAID grant for TB vaccine

Friday, March 23, 2012 01:06 PM

Emergent BioSolutions has received a multi-year grant from the National Institute of Allergy and Infectious Diseases (NIAID) to advance the development of MVA85A, a candidate vaccine against tuberculosis (TB).

More... »

NIH to join multi-center trial of new tuberculosis vaccine

Tuesday, February 7, 2012 07:34 AM

The National Institute of Allergy and Infectious Diseases (NIAID), part of the U.S. National Institutes of Health (NIH), has joined a phase II proof-of-concept clinical trial of a tuberculosis (TB) vaccine candidate jointly developed by Aeras and Dutch biopharmaceutical company Crucell.

More... »

Taplmmune, Aeras ink research collaboration

Thursday, November 3, 2011 09:55 AM

TapImmune has signed a research collaboration with Aeras. The overall goal of this collaboration will be to evaluate the efficacy of TAP in concert with novel vaccine vectors encoding TB immunogens under development at Aeras with the aim of advancing suitable candidates to clinical development. Aeras will conduct all pre-clinical development studies at their laboratories in Rockville, MD.

More... »

CenterWatch Data Library
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

October 20

Toronto Star, with FDA data, exposes weaknesses in Health Canada's clinical trial, inspection oversight

Crowdsourcing effort aims to fund updated online social media guide for sponsor interaction with patients

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

September

Today's fastest, most economical sponsors
Standout sponsors reveal how they shorten regulatory, clinical cycle times

From the trenches: Sites' eye view of state of the industry
CW’s first site focus groups uncover frustration with 'progress,' but a passion for their mission

Already a subscriber?
Log in to your digital subscription.

Purchase the September issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

August

Reality of costs and impact rain on Sunshine Act
Concerns mount over compliance burden on CROs, sponsors, unanticipated consequences for research

Cloud computing expanding into all areas of clinical trial conduct
Benefits outweigh the complexities, challenges of finding right vendors

Already a subscriber?
Log in to your digital subscription.

Purchase the August issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs